Breast Cancer Research and Treatment

Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210
pp. 199-207(9)
Authors: Watanabe M.; Wallace P.K.; Keler T.; Deo Y.M.; Akewanlop C.; Hayes D.F.

Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’
pp. 209-215(7)
Authors: Demicheli R.; Miceli R.; Brambilla C.; Ferrari L.; Moliterni A.; Zambetti M.; Valagussa P.; Bonadonna G.

Pattern of distribution of cells positive for estrogen receptor and progesterone receptor in relation to proliferating cells in the mammary gland
pp. 217-227(11)
Authors: Russo J.; Ao X.; Grill C.; Russo I.H.

Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells
pp. 229-240(12)
Authors: Daschner P.J.; Ciolino H.P.; Plouzek C.A.; Yeh G.C.

Diet and risk for breast cancer recurrence and survival
pp. 241-253(13)
Authors: Saxe G.A.; Rock C.L.; Wicha M.S.; Schottenfeld D.

Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients
pp. 255-262(8)
Authors: Cohen I.; Perel E.; Tepper R.; Flex D.; Figer A.; Shapira J.; Altaras M.M.; Fishman A.; Bernheim J.; Cordoba M.; Yigael o.; Beyth Y.

Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis
pp. 263-269(7)
Authors: Shao Z-m.; Li J.; Wu J.; Han Q-x.; Shen Z-z.; Fontana J.A.; Barsky S.H.

Tamoxifen and risk of large bowel cancer in women with breast cancer
pp. 271-277(7)
Authors: Newcomb P.A.; Solomon C.; White E.

Recognition of an epitope of a breast cancer antigen by human antibody
pp. 279-290(12)
Authors: Cao J-n.; Gao T-w.; Giuliano A.E.; Irie R.F.